Cancer vaccine aims to prevent leukemia relapse in older adults

NCT ID NCT03059485

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Feb 01, 2026 · Last updated Jun 12, 2026 · Updated 16 times

Summary

This study tests a personalized vaccine made from a patient's own leukemia cells and immune cells. The goal is to see if the vaccine can help prevent the cancer from coming back after chemotherapy. It is for adults aged 55 and older with acute myeloid leukemia (AML) who are in remission. Half of the participants receive the vaccine, and the other half are simply watched.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital

Boston, Massachusetts, 02214, United States
University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOGENOUS LEUKEMIA